CN113244183A - 一种肌苷的口腔速溶片及其制备方法 - Google Patents
一种肌苷的口腔速溶片及其制备方法 Download PDFInfo
- Publication number
- CN113244183A CN113244183A CN202110633120.5A CN202110633120A CN113244183A CN 113244183 A CN113244183 A CN 113244183A CN 202110633120 A CN202110633120 A CN 202110633120A CN 113244183 A CN113244183 A CN 113244183A
- Authority
- CN
- China
- Prior art keywords
- inosine
- percent
- agent
- orally
- tablet according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930010555 Inosine Natural products 0.000 title claims abstract description 56
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 title claims abstract description 56
- 229960003786 inosine Drugs 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 20
- 238000007873 sieving Methods 0.000 claims abstract description 20
- 238000002156 mixing Methods 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000000945 filler Substances 0.000 claims abstract description 9
- 239000000314 lubricant Substances 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 8
- 238000010298 pulverizing process Methods 0.000 claims abstract description 8
- 239000000796 flavoring agent Substances 0.000 claims abstract description 7
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 7
- 239000007884 disintegrant Substances 0.000 claims abstract description 6
- 230000002378 acidificating effect Effects 0.000 claims abstract description 5
- 239000000853 adhesive Substances 0.000 claims abstract description 5
- 230000001070 adhesive effect Effects 0.000 claims abstract description 5
- 238000001035 drying Methods 0.000 claims abstract description 4
- 239000008187 granular material Substances 0.000 claims abstract description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
- 238000005303 weighing Methods 0.000 claims abstract description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 30
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 17
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 17
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 17
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 235000019359 magnesium stearate Nutrition 0.000 claims description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- 229930195725 Mannitol Natural products 0.000 claims description 10
- 235000015165 citric acid Nutrition 0.000 claims description 10
- 239000000594 mannitol Substances 0.000 claims description 10
- 235000010355 mannitol Nutrition 0.000 claims description 10
- 239000000741 silica gel Substances 0.000 claims description 10
- 108010011485 Aspartame Proteins 0.000 claims description 9
- 239000000605 aspartame Substances 0.000 claims description 9
- 235000010357 aspartame Nutrition 0.000 claims description 9
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 9
- 229960003438 aspartame Drugs 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 235000010356 sorbitol Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 229940013618 stevioside Drugs 0.000 claims description 5
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 5
- 235000019202 steviosides Nutrition 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 239000004378 Glycyrrhizin Substances 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940049654 glyceryl behenate Drugs 0.000 claims description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 2
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 235000014380 magnesium carbonate Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 235000016337 monopotassium tartrate Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 229940086065 potassium hydrogentartrate Drugs 0.000 claims description 2
- 229940085605 saccharin sodium Drugs 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 229940037627 magnesium lauryl sulfate Drugs 0.000 claims 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 25
- 239000003814 drug Substances 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 229960001855 mannitol Drugs 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 206010013911 Dysgeusia Diseases 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 229960002920 sorbitol Drugs 0.000 description 4
- 238000000643 oven drying Methods 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 229910021487 silica fume Inorganic materials 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 101100273639 Carassius auratus ccna1 gene Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- -1 lauryl magnesium sulfate Chemical compound 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000007944 soluble tablet Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000000152 swallowing effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种肌苷的口腔速溶片,以重量百分比含量计:肌苷为30%‑60%;药用辅料40‑70%;其中,药用辅料包括崩解剂5%‑10%、泡腾剂0.5%‑10%、粘合剂0%‑5%、润滑剂1%‑5%、矫味剂1%‑2%、余量为填充剂;制剂规格为50‑400mg。一种肌苷的口腔速溶片的制备方法,步骤1:将肌苷粉碎过100‑150目筛,辅料过50‑80目筛,分别保存备用;步骤2:按处方量称取肌苷、填充剂、崩解剂、矫味剂及碱性泡腾剂,并将其充分混合均匀;步骤3:将上述均匀混合的组分,采用湿法制粒,然后在40‑80℃烘干,整粒;步骤4:在上述颗粒中加入酸性泡腾剂、润滑剂,充分混合均匀;步骤5:压片。
Description
技术领域
本发明涉及一种肌苷的口腔速溶片。
本发明还涉及一种肌苷的口腔速溶片的制备方法。
背景技术
肌苷用作辅酶类药物。肌苷是机体内ATP、辅酶A、核糖核酸及脱氧核糖核酸的组成部分,参与机体的物质代谢和能量代谢。它能提高机体ATP的水平,可转化为多种核苷酸,并参与蛋白质的合成。肌苷对细胞膜有良好的通透性,能直接进入细胞,转变为核苷酸,再进一步变成ATP参与代谢,有促进肝细胞恢复,防止脂肪肝的作用,并能提高各种酶的活性,刺激机体产生抗体。在急、慢性肝炎、肝硬化导致肝功能异常时,肌苷可作为一辅助保肝药使用,也可用于抢救肝昏迷。
目前肌苷上市制剂有片剂、胶囊剂、口服溶液、注射剂。规格多为200mg。片剂、胶囊剂服用需大量饮水,口服液携带不便,注射剂应用不便。
口腔速溶片在遇到唾液后,短时间内即可迅速崩解和溶解,使药物呈液体状态,随着吞咽动作由食管进入胃。口腔速溶片一般采用如下工艺制备:(1)冷冻干燥工艺:工艺较成熟、产品临床效果理想,但成本高,须大型冷冻干燥设备,生产周期长,产品空隙均一度不好,不能有效掩盖药物不良味道,制备中要严格控制条件;(2)固态溶液技术,片剂强度较冷冻干燥片有所提高,空隙均一,但溶剂、药物的选择有一定限制,成本高,药物大多数必须在形成骨架后再加入;(3)喷雾干燥工艺:片剂强度大,完整性好,但药物选择有一定范围,辅料范围有限,工艺较复杂;(4)直接压片工艺:成本低,制备简单,缺点是药物剂量不能过大,而且要控制辅料流动性。
由以上可知,因肌苷规格较大,难以通过直接压片法制备口溶片,而且还要同时兼顾肌苷口味掩盖,提高肌苷溶解性能等难题。
因此,直接压片法制备肌苷口溶片难度较大。
发明内容
为解决上述技术问题,本发明提供一种肌苷的口腔速溶片。
本发明还提供一种肌苷的口腔速溶片的制备方法。制备的肌苷可迅速崩解、释放和遮蔽不良味觉。
本发明提供如下技术方案:
一种肌苷的口腔速溶片,除了主药肌苷外,还包括药用辅料,以重量百分比含量计:
肌苷为 30%-60%;
药用辅料 40-70%;
其中,药用辅料包括崩解剂5%-10%、泡腾剂0.5%-10%、粘合剂0%- 5%、润滑剂1%-5%、矫味剂1%-2%、余量为填充剂;制剂规格为50-400mg。
进一步的,制剂规格为200mg。
口腔速溶片的关键是在水中的崩解、溶解速度, 所以药片中的崩解剂体系选择非常重要,本发明选择的崩解剂包括羧甲基淀粉钠(CMS-Na)、交联羧甲基淀粉钠(CCNa)、低取代羟丙基纤维素(L-HPC)、交联聚乙烯吡咯烷酮(PVPP)中的一种或多种。
填充剂是用以增加片剂重量和体积,利于成型, 本发明口腔速溶片的填充剂包括乳糖、蔗糖、 甘露醇、山梨醇、麦芽糖、预胶化淀粉中的一种或多种。
本发明中口腔速溶片的粘合剂包括聚乙烯吡咯烷酮(PVP)、羟丙基纤维素、羟丙甲基纤维素中的一种或多种辅料的水或醇的溶液,也可直接用水、不同浓度乙醇溶液。
本发明口腔速溶片使用的润滑剂包括硬脂酸镁、硬脂酸钙、聚乙二醇、二氧化硅、微粉硅胶、滑石粉、十二烷基硫酸镁、十二烷基硫酸钠、硬脂富马酸钠、山嵛酸甘油酯中的一种或多种。
本发明使用的矫味剂包括阿司巴甜、甘草甜素、甜菊甙、糖精钠、药用香精中的一种或多种。
泡腾剂中碱性泡腾剂包括碳酸氢钠、碳酸氢钾、碳酸钠、碳酸钾、碳酸钙、碳酸镁中的一种或多种。
泡腾剂中酸性泡腾剂包括柠檬酸、酒石酸、酒石酸氢钾、苹果酸中的一种或多种。
与现有技术相比,本发明的有益效果是:采用压片法制备口腔速溶片,高主药含量,味道好,无明显不良口味,服用方便,患者顺应性好。
一种肌苷的口腔速溶片的制备方法,包括以下步骤:
步骤1:将肌苷粉碎过100-150目筛,辅料过50-80目筛,分别保存备用;
步骤2:按处方量称取肌苷、填充剂、崩解剂、矫味剂及碱性泡腾剂,并将其充分混合均匀;
步骤3:将上述均匀混合的组分,采用湿法制粒,然后在40-80℃烘干,整粒;
步骤4:在上述颗粒中加入酸性泡腾剂、润滑剂,充分混合均匀;
步骤5:压片。
本发明涉及的肌苷口腔速溶片服用方便,口感好,在口腔中遇到唾液就能够迅速崩解、溶解,给一些老年人、儿童或有吞服药物障碍、取水不便的患者提供了便利。
具体实施方式
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
处方 重量百分比含量
肌苷 30%;
交联聚乙烯吡咯烷酮 8%;
碳酸氢钠 1%;
柠檬酸 0.5%;
硬脂酸镁 0.5%;
微粉硅胶 4%;
阿司巴甜 0.5%;
桔子香精 0.5%;
其余是甘露醇加至100%。
制备方法:
将肌苷粉碎过100目筛,辅料过50目筛,将肌苷、甘露醇、交联聚乙烯吡咯烷酮、等上述各辅料充分混合均匀, 最后加入硬脂酸镁及微粉硅胶,混合均匀,直接压片。
实施例2:
处方 重量百分比含量
肌苷 40%;
交联聚乙烯吡咯烷酮 10%;
碳酸氢钠 1%;
柠檬酸 1%;
硬脂酸镁 0.5%;
微粉硅胶 1%;
阿司巴甜 1%;
桔子香精 0.5%;
其余是甘露醇加至100%。
制备方法:
将肌苷粉碎过150目筛,辅料过80目筛,将50%处方量的肌苷及甘露醇、山梨醇、阿司巴甜、桔子香精、交联聚乙烯吡咯烷酮、碳酸氢钠混合均匀,用PVP无水乙醇溶液制软材,过20目筛制粒,在40℃下烘干;另50%处方量的主、辅料与柠檬酸充分混合均匀,加入PVP的无水乙醇溶液制软材,过20目筛制粒,在40℃下烘干,整粒后将两部分颗粒充分混匀,加入硬脂酸镁及微粉硅胶,混合均匀,压片。
实施例3:
处方 重量百分比含量
肌苷 50%;
羧甲基淀粉钠 5%;
碳酸氢钠 10%;
柠檬酸 10%;
硬脂酸镁 0.5%;
微粉硅胶 1.5%;
甜菊甙 1%;
桔子香精 1%;
其余是甘露醇加至100%。
制备方法;
将肌苷粉碎过100目筛,辅料过50目筛,将肌苷、甘露醇、CMS -Na等上述各辅料充分混合均匀, 最后加入硬脂酸镁及微粉硅胶,混合均匀,直接压片。
实施例4:
处方 重量百分比含量
肌苷 30%;
交联聚乙烯吡咯烷酮 5%;
碳酸氢钠 1%;
柠檬酸 1%;
硬脂酸镁 0.5%;
微粉硅胶 0.5%;
阿司巴甜 0.5%;
甜菊甙 0.5%;
桔子香精 0.5%;
其余是甘露醇加至100%。
制备方法:
将肌苷粉碎过120目筛,辅料过80目筛,将处方量的肌苷及甘露醇、阿司巴甜、甜菊甙、桔子香精、交联聚乙烯吡咯烷酮、碳酸氢钠混合均匀,用PVP乙醇溶液制软材,过20目筛制粒,在40℃下烘干;加入柠檬酸、硬脂酸镁及微粉硅胶,混合均匀,直接压片。
实施例5:
处方 重量百分比含量
肌苷 60%;
交联聚维酮 6%;
低取代羟丙基纤维素 1%;
碳酸氢钠 4%;
柠檬酸 4%;
硬脂酸镁 1%;
微粉硅胶 1%;
阿司巴甜 0.5%;
桔子香精 1.5%;
其余是山梨醇加至100%。
制备方法;
将肌苷粉碎过120目筛,辅料过80目筛,将处方量的肌苷及山梨醇、阿司巴甜、桔子香精、交联聚乙烯吡咯烷酮、柠檬酸混合均匀,用PVP乙醇溶液制软材,过20目筛制粒,在40℃下烘干;加入碳酸氢钠、硬脂酸镁及微粉硅胶,混合均匀,直接压片。
实施例中所得各样品片的性能检测:
以上各实施例中样品片均达到了要求的1min内崩解的要求。
采用压片法制备口溶片,高主药含量,味道好,无明显不良口味,服用方便,患者顺应性好。
本发明涉及的肌苷口腔速溶片服用方便,口感好,在口腔中遇到唾液就能够迅速崩解、溶解,给一些老年人、儿童或有吞服药物障碍、取水不便的患者提供了便利。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (9)
1.一种肌苷的口腔速溶片,其特征在于,以重量百分比含量计:
肌苷为 30%-60%;
药用辅料 40-70%;
其中,药用辅料包括崩解剂5%-10%、泡腾剂0.5%-10%、粘合剂0%- 5%、润滑剂1%-5%、矫味剂1%-2%、余量为填充剂;制剂规格为50-400mg。
2.根据权利要求1所述的一种肌苷的口腔速溶片,其特征在于:所述崩解剂包括羧甲基淀粉钠、交联羧甲基淀粉钠、低取代羟丙基纤维素、交联聚乙烯吡咯烷酮中的一种或多种。
3.根据权利要求1所述的一种肌苷的口腔速溶片,其特征在于:所述填充剂包括乳糖、蔗糖、 甘露醇、山梨醇、麦芽糖、预胶化淀粉中的一种或多种。
4.根据权利要求1所述的一种肌苷的口腔速溶片,其特征在于:所述粘合剂包括聚乙烯吡咯烷酮(PVP)、羟丙基纤维素、羟丙甲基纤维素中的一种或多种辅料的水或醇的溶液,也可直接用水、不同浓度乙醇溶液。
5.根据权利要求1所述的一种肌苷的口腔速溶片,其特征在于:所述润滑剂包括硬脂酸镁、硬脂酸钙、聚乙二醇、二氧化硅、微粉硅胶、滑石粉、十二烷基硫酸镁、十二烷基硫酸钠、硬脂富马酸钠、山嵛酸甘油酯中的一种或多种。
6.根据权利要求1所述的一种肌苷的口腔速溶片,其特征在于:所述矫味剂包括阿司巴甜、甘草甜素、甜菊甙、糖精钠、药用香精中的一种或多种。
7.根据权利要求1所述的一种肌苷的口腔速溶片,其特征在于:所述泡腾剂中碱性泡腾剂包括碳酸氢钠、碳酸氢钾、碳酸钠、碳酸钾、碳酸钙、碳酸镁中的一种或多种。
8.根据权利要求1所述的一种肌苷的口腔速溶片,其特征在于:所述泡腾剂中酸性泡腾剂包括柠檬酸、酒石酸、酒石酸氢钾、苹果酸中的一种或多种。
9.根据权利要求1所述的一种肌苷的口腔速溶片的制备方法,其特征在于:
步骤1:将肌苷粉碎过100-150目筛,辅料过50-80目筛,分别保存备用;
步骤2:按处方量称取肌苷、填充剂、崩解剂、矫味剂及碱性泡腾剂,并将其充分混合均匀;
步骤3:将上述均匀混合的组分,采用湿法制粒,然后在40-80℃烘干,整粒;
步骤4:在上述颗粒中加入酸性泡腾剂、润滑剂,充分混合均匀;
步骤5:压片。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110633120.5A CN113244183A (zh) | 2021-06-07 | 2021-06-07 | 一种肌苷的口腔速溶片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110633120.5A CN113244183A (zh) | 2021-06-07 | 2021-06-07 | 一种肌苷的口腔速溶片及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113244183A true CN113244183A (zh) | 2021-08-13 |
Family
ID=77186868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110633120.5A Pending CN113244183A (zh) | 2021-06-07 | 2021-06-07 | 一种肌苷的口腔速溶片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113244183A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101829137A (zh) * | 2009-03-09 | 2010-09-15 | 北京利乐生制药科技有限公司 | 一种以胞磷胆碱钠和肌苷为活性成分的固体制剂及其应用 |
CN102933207A (zh) * | 2009-10-30 | 2013-02-13 | Ix生物医药私人有限公司 | 快速溶解固体剂型 |
-
2021
- 2021-06-07 CN CN202110633120.5A patent/CN113244183A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101829137A (zh) * | 2009-03-09 | 2010-09-15 | 北京利乐生制药科技有限公司 | 一种以胞磷胆碱钠和肌苷为活性成分的固体制剂及其应用 |
CN102933207A (zh) * | 2009-10-30 | 2013-02-13 | Ix生物医药私人有限公司 | 快速溶解固体剂型 |
Non-Patent Citations (1)
Title |
---|
万东华,周建平: "微泡型口腔速释片的制备", 中国药科大学学报, no. 03, pages 228 - 231 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4989733B2 (ja) | 口腔内崩壊錠 | |
US20090311321A1 (en) | Oral disintegrating tablet having masked bitter taste and method for production thereof | |
CN102657629B (zh) | 替卡格雷缓释片系统及其制备方法 | |
WO2002069934A1 (fr) | Préparations se délitant rapidement dans la bouche | |
KR20000062327A (ko) | 속붕괴성 의약 조성물 | |
JP2008285434A (ja) | 口腔内速崩壊錠 | |
JP2002255796A (ja) | 口腔内速崩壊型錠剤及びその製造方法 | |
CN101401797A (zh) | 一种含有甲磺酸伊马替尼的泡腾片及其制备方法 | |
EP2848242A1 (en) | Orally disintegrating formulations of Linagliptin | |
CN101401795A (zh) | 一种甲磺酸伊马替尼口腔崩解片及其制备方法 | |
CN105395504A (zh) | 一种盐酸氟桂利嗪骨架缓释片及其制备方法 | |
JP2007119453A (ja) | 塩酸ブロムヘキシン含有量低下の防止方法 | |
EP3238712B1 (en) | Very rapidly disintegrating tablet, and method for producing same | |
JPH06157312A (ja) | 苦味改善テルフェナジンドライシロップ顆粒剤 | |
CN113244183A (zh) | 一种肌苷的口腔速溶片及其制备方法 | |
KR101046789B1 (ko) | 안정성이 개선된 암로디핀 속붕해성 정제 및 그의 제조방법 | |
CN101797235B (zh) | 卡络磺钠口腔崩解片及其制备方法 | |
CN101732725B (zh) | 一种加速片剂崩解的组合物及其应用 | |
WO2003075919A1 (fr) | Comprime contenant du chlorhydrate de pilsicainide (voie seche) | |
JP2002138055A (ja) | 口腔内速崩壊性圧縮成型物およびその製造方法 | |
JP4695581B2 (ja) | 口腔内速崩壊性錠剤 | |
KR101485177B1 (ko) | 쓴맛이 차폐된 실데나필 시트레이트의 저작정 및 그 제조방법 | |
WO2013098399A1 (en) | Mozavaptan formulations | |
JP4393119B2 (ja) | ヨウ化イソプロパミド含有製剤 | |
CN101664393A (zh) | 甲磺酸普立地诺口腔崩解片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210813 |